That’s in USD I believe. In AUD, capturing just 10% of total anthracycline market would be around $200 per share. And assuming first-in-class and best-in-class CPACS validation, 10% market share sounds fairly conservative in my opinion…
To paraphrase Dr T, do we really think based on available information that Race has less than 1% chance of succeeding? Personally, I think it’s much higher.
Cardioprotection thread, page-472
-
- There are more pages in this discussion • 435 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
